|
1
|
Landen CN Jr, Birrer MJ and Sood AK: Early
events in the pathogenesis of epithelial ovarian cancer. J Clin
Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Engel J, Eckel R, Schubert-Fritschle G,
Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J and Hölzel D:
Moderate progress for ovarian cancer in the last 20 years:
Prolongation of survival, but no improvement in the cure rate. Eur
J Cancer. 38:2435–2445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohyagi-Hara C, Sawada K, Kamiura S, Tomita
Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T,
Takahashi T, et al: miR-92a inhibits peritoneal dissemination of
ovarian cancer cells by inhibiting integrin α5 expression. Am J
Pathol. 182:1876–1889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lessan K, Aguiar DJ, Oegema T, Siebenson L
and Skubitz AP: CD44 and beta1 integrin mediate ovarian carcinoma
cell adhesion to peritoneal mesothelial cells. Am J Pathol.
154:1525–1537. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Strobel T and Cannistra SA:
Beta1-integrins partly mediate binding of ovarian cancer cells to
peritoneal mesothelium in vitro. Gynecol Oncol. 73:362–367. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sawada K, Ohyagi-Hara C, Kimura T and
Morishige K: Integrin inhibitors as a therapeutic agent for ovarian
cancer. J Oncol. 2012:9151402012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hodkinson PS, Elliott T, Wong WS, Rintoul
RC, Mackinnon AC, Haslett C and Sethi T: ECM overrides DNA
damage-induced cell cycle arrest and apoptosis in small-cell lung
cancer cells through beta1 integrin-dependent activation of
PI3-kinase. Cell Death Differ. 13:1776–1788. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sawada K, Mitra AK, Radjabi AR, Bhaskar V,
Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A,
Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer
metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morgan MR, Byron A, Humphries MJ and Bass
MD: Giving off mixed signals–distinct functions of alpha5beta1 and
alphavbeta3 integrins in regulating cell behaviour. IUBMB Life.
61:731–738. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marelli UK, Rechenmacher F, Sobahi TR,
Mas-Moruno C and Kessler H: Tumor targeting via integrin ligands.
Front Oncol. 3:2222013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wintzell M, Hjerpe E, Åvall Lundqvist E
and Shoshan M: Protein markers of cancer-associated fibroblasts and
tumor-initiating cells reveal subpopulations in freshly isolated
ovarian cancer ascites. BMC Cancer. 12:3592012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe T, Hashimoto T, Sugino T, Soeda
S, Nishiyama H, Morimura Y, Yamada H, Goodison S and Fujimori K:
Production of IL1-beta by ovarian cancer cells induces mesothelial
cell beta1-integrin expression facilitating peritoneal
dissemination. J Ovarian Res. 5:72012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sawada K, Radjabi AR, Shinomiya N, Kistner
E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande
Woude GF, et al: c-Met overexpression is a prognostic factor in
ovarian cancer and an effective target for inhibition of peritoneal
dissemination and invasion. Cancer Res. 67:1670–1679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun C, Li N, Yang Z, Zhou B, He Y, Weng D,
Fang Y, Wu P, Chen P, Yang X, et al: miR-9 regulation of BRCA1 and
ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl
Cancer Inst. 105:1750–1758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Li J, Ding X, He M and Cheng SY:
microRNA and cancer. AAPS J. 12:309–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yi L, Zongyuan Y, Cheng G, Lingyun Z,
Guilian Y and Wei G: Quercetin enhances apoptotic effect of tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) in
ovarian cancer cells through reactive oxygen species (ROS) mediated
CCAAT enhancer-binding protein homologous protein (CHOP)-death
receptor 5 pathway. Cancer Sci. 105:520–527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo W and Giancotti FG: Integrin
signalling during tumour progression. Nat Rev Mol Cell Biol.
5:816–826. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Persad S and Dedhar S: The role of
integrin-linked kinase (ILK) in cancer progression. Cancer
Metastasis Rev. 22:375–384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hannigan G, Troussard AA and Dedhar S:
Integrin-linked kinase: A cancer therapeutic target unique among
its ILK. Nat Rev Cancer. 5:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng JM, Chen YH, Hung SW, Chiu CF, Ho MY,
Lee YJ, Lai TC, Hsiao M, Liang CM and Liang SM: Recombinant viral
protein promotes apoptosis and suppresses invasion of ovarian
adenocarcinoma cells by targeting α5β1 integrin to down-regulate
Akt and MMP-2. Br J Pharmacol. 165:479–493. 2012. View Article : Google Scholar :
|
|
22
|
Jin H and Varner J: Integrins: Roles in
cancer development and as treatment targets. Br J Cancer.
90:561–565. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwanicki MP, Davidowitz RA, Ng MR, Besser
A, Muranen T, Merritt M, Danuser G, Ince TA and Brugge JS: Ovarian
cancer spheroids use myosin-generated force to clear the
mesothelium. Cancer Discov. 1:144–157. 2011. View Article : Google Scholar
|
|
24
|
Fine RN: Growth after renal
transplantation in children. J Pediatr. 110:414–416. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ebi H, Sato T, Sugito N, Hosono Y, Yatabe
Y, Matsuyama Y, Yamaguchi T, Osada H, Suzuki M and Takahashi T:
Counterbalance between RB inactivation and miR-17-92 overexpression
in reactive oxygen species and DNA damage induction in lung
cancers. Oncogene. 28:3371–3379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y
and Fan D: miR-17-5p promotes proliferation by targeting SOCS6 in
gastric cancer cells. FEBS Lett. 588:2055–2062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei Q, Li YX, Liu M, Li X and Tang H:
MiR-17-5p targets TP53INP1 and regulates cell proliferation and
apoptosis of cervical cancer cells. IUBMB Life. 64:697–704. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Y, Luo LH, Li S and Yang C: miR-17
inhibitor suppressed osteosarcoma tumor growth and metastasis via
increasing PTEN expression. Biochem Biophys Res Commun.
444:230–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma Y, Zhang P, Wang F, Zhang H, Yang Y,
Shi C, Xia Y, Peng J, Liu W, Yang Z, et al: Elevated oncofoetal
miR-17-5p expression regulates colorectal cancer progression by
repressing its target gene P130. Nat Commun. 3:12912012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kesanakurti D, Chetty C, Dinh DH, Gujrati
M and Rao JS: Role of MMP-2 in the regulation of IL-6/Stat3
survival signaling via interaction with α5β1 integrin in glioma.
Oncogene. 32:327–340. 2013. View Article : Google Scholar
|
|
31
|
Bell-McGuinn KM, Matthews CM, Ho SN, Barve
M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos
A, et al: A phase II, single-arm study of the anti-α5β1 integrin
antibody volociximab as monotherapy in patients with
platinum-resistant advanced epithelial ovarian or primary
peritoneal cancer. Gynecol Oncol. 121:273–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
